Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial

Vico M. R., Wetterskog D., Thakali S., Orlando F., Jayaram A. K., Vainauskas O., ...More

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 20 - 24 October 2023, (Summary Text) identifier

  • Publication Type: Conference Paper / Summary Text
  • Doi Number: 10.1016/j.annonc.2023.09.2784
  • City: Barcelona
  • Country: Spain
  • Dokuz Eylül University Affiliated: Yes